Navigation Links
Standard chemotherapy provides higher survival rate than experimental in lung cancer patients
Date:9/6/2012

Treatment with pemetrexed, carboplatin and bevacizumab followed by maintenance pemetrexed and bevacizumab (Pem+Cb+B) is no better than standard therapy with paclitaxel, carboplatin and bevacizumab followed by bevacizumab (Pac+Cb+B) in patients with advanced non-squamous non-small cell lung cancer (NS-NSCLC), according to research presented at the 2012 Chicago Multidisciplinary Symposium in Thoracic Oncology. This symposium is sponsored by the American Society of Clinical Oncology (ASCO), the American Society for Radiation Oncology (ASTRO), the International Association for the Study of Lung Cancer (IASLC) and The University of Chicago.

According to the American Cancer Society, lung cancer is the number one cause of cancer deaths in men and women each year. The current standard treatment for advanced NS-NSCLC patients, the most common form of advanced NSCLC, is either Pac+Cb+B or pemetrexed plus cisplatin. This trial sought to define a new standard of care by comparing Pac+Cb+B to the experimental chemotherapy regimen Pem+Cb+B to determine if either improved overall survival for late-stage lung cancer patients. Pemetrexed plus cisplatin was not tested in this trial.

The 939 patients were randomized to receive one of the two treatment arms every three weeks for up to four cycles. The patients received the same arm for each cycle. Overall survival was not statistically different between the two arms, 12.6 months in Pem+Cb+ Bev versus 13.4 months for the Pac+Cb+B arm, The experimental arm of Pem+Cb+Bev led to a increase in time before progression of disease (PFS) compared with the standard arm of Pac+ Cb+Bev6 months versus 5.6 months, respectively.

"The fact that there was no improvement in survival with the experimental regimen was disappointing, but these findings are important as we continue to navigate ways to improve survival for this devastating disease," said Jyoti Patel, MD, lead author of the study and an associate professor in Medicine-Hematology/Oncology at Northwestern University in Chicago. "It is important to note that both regimens demonstrated tolerability, although their toxicities differed. These differences can be important for our patients."


'/>"/>

Contact: Michelle Kirkwood
michellek@astro.org
American Society for Radiation Oncology
Source:Eurekalert

Related medicine news :

1. Job injuries among youth prompt calls for better safety standards
2. Can a standard vision test predict nighttime driving performance?
3. Adding drug to standard chemotherapy provides no survival benefit for older lung cancer patients
4. New Psoriasis Drugs Not Much Better Than Standard Therapy, Study Finds
5. New standards for treating traumatic shoulder injuries to improve patient care
6. MR enterography is as good or better than standard imaging exams for pediatric Crohns patients
7. Low-dose whole-body CT finds disease missed on standard imaging for patients with multiple myeloma
8. First, do no harm: Study finds danger in standard treatment for a serious lung disease
9. Mayo Clinic: Standard heart disease risk tools underrate danger in rheumatoid arthritis
10. Standard Process Inc.’s Marketing Team Wins Six Awards
11. Local Woodinville Contractor, Washington State Kitchen and Bath, Combats Toxic Mold, Adhering to the Toughest Mold Protection Standards in the Nation with New Promotion
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... ... February 24, 2017 , ... Indiana Fiber Network (IFN) ... company later this year. Dyer started as the Chairman of the Management Committee ... establishment of the corporation including the recruitment of investor/owners and development of the business ...
(Date:2/24/2017)... MI (PRWEB) , ... February 24, 2017 , ... ... in Charlevoix, once again hosted their Military Wedding Giveaway, with the winning ... hosted by Castle Farms with services generously donated from local vendors: A Matter ...
(Date:2/23/2017)... ... February 23, 2017 , ... The Lymphoma ... innovative lymphoma research and serving the lymphoma community through a comprehensive series of ... Gorce Country Club in Miami Beach to host its Swirl: Miami Wine Tasting ...
(Date:2/23/2017)... ... ... Hamlin Dental Group and Dr. Hamid Reza, dentist in North Hollywood ... of February, patients who visit Hamlin Dental Group will receive a ticket for a ... the Cheesecake Factory. , Tickets are available for routine dental visits and other ...
(Date:2/23/2017)... Nevada (PRWEB) , ... February 23, 2017 , ... Dr. ... Avenue in Henderson, NV 89052. Dr. Mahon was named a 2017 Top Patient Rated ... Doctors is an online directory that recognizes local physicians and dentists who have ...
Breaking Medicine News(10 mins):
(Date:2/23/2017)... 23. Februar 2017 LG Innotek hat heute ... Die Sterilisationsleistung beträgt das 1,5-fache des 45-mW-Moduls der Konkurrenz. ... Bereich zwischen 200 und 280 nm und eignet sich damit ... es ihre DNA zerstört. Das Produkt von LG Innotek ... ...
(Date:2/23/2017)... and Markets has announced the addition of the "Menopause Drugs Price ... ... Analysis and Strategies - 2016, provides drug pricing data and benchmarks in ... What are the key drugs marketed for Menopause ... market? What are the unit prices and annual treatment ...
(Date:2/23/2017)... Calif. , Feb. 23, 2017 ... company focused on the development and commercialization of ... pain, announced that it will release fourth quarter ... Thursday, March 2nd, 2017. AcelRx management will host ... Time (1:30 p.m. Pacific Time) on March 2 ...
Breaking Medicine Technology: